HARMONY BIOSCIENCES HOLDINGS (HRMY) Stock News
NASDAQ:HRMY - Nasdaq - US4131971040 - Common Stock
HRMY Latest News and Analysis
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels.
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits.
Harmony Biosciences Reports Strong 2024 Revenues, Provides 2025 Revenue Guidance and Highlights Key Pipeline Catalysts
Investors should take note of NASDAQ:HRMY, a growth stock that remains attractively priced.
Don't overlook HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY)—a stock with solid growth prospects and a reasonable valuation.
Don't overlook NASDAQ:HRMY—it's a hidden gem with strong fundamentals and an attractive price tag.
HARMONY BIOSCIENCES HOLDINGS (NASDAQ:HRMY), an undervalued stock with good fundamentals.
First Week of HRMY February 2025 Options Trading
HARMONY BIOSCIENCES TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in...
HRMY Makes Notable Cross Below Critical Moving Average
HARMONY BIOSCIENCES TO PARTICIPATE IN OPPENHEIMER MOVERS IN RARE DISEASE SUMMIT
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the...
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming...
Harmony Biosciences Holdings, Inc. Announces Pricing of Public Offering of Common Stock by Selling Shareholders
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the pricing of the previously announced underwritten public...
Axonis Therapeutics Announces $115 Million Series A Financing
/PRNewswire/ -- Axonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of...
Harmony Biosciences Holdings, Inc. Announces Commencement of Proposed Public Offering of Common Stock by Selling Shareholders
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) (the "Company") today announced the commencement of an underwritten public offering of up to...
Harmony Biosciences (HRMY) Q3 2024 Earnings Call Transcript
HRMY earnings call for the period ending September 30, 2024.
Harmony Bio, The No. 1 Biotech Stock, Surged On Its 'High-Quality' Beat
The company is focused on developing its pipeline of sleep and epilepsy drugs.
HARMONY BIOSCIENCES REPORTS STRONG THIRD QUARTER 2024 FINANCIAL RESULTS AND HIGHLIGHTS CATALYST-RICH, LATE-STAGE PIPELINE POISED TO DELIVER ONE OR MORE NEW LAUNCHES EVERY YEAR OVER NEXT FIVE YEARS
WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years On Track to Submit...
HARMONY BIOSCIENCES TO REPORT THIRD QUARTER 2024 FINANCIAL RESULTS ON OCTOBER 29, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2024 financial results on Tuesday, October...
HARMONY BIOSCIENCES HIGHLIGHTS NEW DATA, ROBUST LATE-STAGE PIPELINE WITH NEAR-TERM VALUE CREATION OPPORTUNITIES AND ITS BOLD NEW VISION AT INVESTOR DAY
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will be providing a comprehensive pipeline update at its Investor Day event today,...
HARMONY BIOSCIENCES TO HOST FIRST INVESTOR DAY ON OCTOBER 1, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), will provide an overview of its robust, late-stage pipeline at an in-person Investor Day at...
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming...
Harmony Biosciences (HRMY) Q2 2024 Earnings Call Transcript
HRMY earnings call for the period ending June 30, 2024.
HRMY Stock Earnings: Harmony Biosciences Beats EPS, Beats Revenue for Q2 2024
HRMY stock results show that Harmony Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Harmony Biosciences Reports Strong Second Quarter 2024 Financial Results and Advances Pitolisant High-Dose Program Toward Expected PDUFA Date in 2028
WAKIX® (pitolisant) Net Revenue of $172.8 Million for Second Quarter 2024; ~29% Growth Year-over-Year Next Generation Pitolisant High-Dose (HD) Program...
HARMONY BIOSCIENCES TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 6, 2024
/PRNewswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report second quarter 2024 financial results on Tuesday, August...